drugset / Trial / NCT05311176
A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase 2, signal generating, open-label, 2-Arm, non-randomized study, in patients with metastatic HER2/neu over-expressing gastric cancer or gastroesophageal adenocarcinomas.
Timeline
- Start
- 2022-08-17
- Primary completion
- 2024-04-04
- Completion
- 2024-04-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IMU-131 | Vaccine | — | Intramuscular |
| Subject | Paclitaxel | Small molecule | — | — |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |
| Subject | Ramucirumab | Monoclonal antibody | — | — |